Calypso Biotech's vision is to give new hope to patients suffering from severe gastro-intestinal diseases.
Calypso Biotech has raised €20M across 1 funding round from 2 investors, most recently a Series A round in Jan 2019. Based in Geneva, Netherlands; founded 2013; active in Healthtech. Acquired by Novartis in 2024. Data as of 7 Aug 2026.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2019-01-01 | Series A | €20M | Gilde Healthcare,INKEF Capital | View deal → |
